Eli Lilly (LLY) Free Cash Flow (2009 - 2026)
Eli Lilly posted quarterly Free Cash Flow of $3.0 billion for Q1 2026, up 1827.56% year-on-year from $156.0 million in Q1 2025, and up 343.58% on a QoQ basis from $677.9 million in Q4 2025.
Eli Lilly (LLY) has 18 years of Free Cash Flow data on file, last reported at $3.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 1827.56% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $11.8 billion (up 216.44% YoY), and the FY2025 full-year result was $9.0 billion, up 138.62% from the prior year.
- Free Cash Flow for Q1 2026 stood at $3.0 billion, up from $677.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $6.7 billion in Q3 2025 and bottomed at -$1.4 billion in Q4 2023.
- The 5-year median for Free Cash Flow is $1.1 billion (2023), against an average of $1.3 billion.
- The widest annual swing landed in 2023, when Free Cash Flow tumbled 219.02%; it then soared 1827.56% in 2026.
- A 5-year view of Free Cash Flow shows it stood at $1.2 billion in 2022, then sank by 219.02% to -$1.4 billion in 2023, then soared by 170.69% to $977.7 million in 2024, then tumbled by 30.66% to $677.9 million in 2025, then surged by 343.58% to $3.0 billion in 2026.
- The last three Free Cash Flow figures came in at $3.0 billion (Q1 2026), $677.9 million (Q4 2025), and $6.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.01 Bn |
| Mar 31, 2026 | 3.01 Bn |
| Dec 31, 2025 | 677.90 Mn |
| Dec 31, 2025 | 677.90 Mn |
| Sep 30, 2025 | 6.75 Bn |
| Sep 30, 2025 | 6.75 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 156.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Dec 31, 2024 | 977.70 Mn |
| Dec 31, 2024 | 977.70 Mn |
| Sep 30, 2024 | 2.36 Bn |
| Sep 30, 2024 | 2.36 Bn |
| Jun 30, 2024 | 241.40 Mn |
| Jun 30, 2024 | 241.40 Mn |
| Mar 31, 2024 | 179.70 Mn |
| Mar 31, 2024 | 179.70 Mn |
| Dec 31, 2023 | -1.38 Bn |
| Dec 31, 2023 | -1.38 Bn |
| Sep 30, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.22 Bn |
| Jun 30, 2023 | -106.30 Mn |
| Jun 30, 2023 | -106.30 Mn |
| Mar 31, 2023 | 1.06 Bn |
| Mar 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.60 Bn |
| Sep 30, 2022 | 1.60 Bn |
| Jun 30, 2022 | 812.30 Mn |
| Jun 30, 2022 | 812.30 Mn |
| Mar 31, 2022 | 2.16 Bn |
| Mar 31, 2022 | 2.16 Bn |
| Dec 31, 2021 | 1.97 Bn |
| Dec 31, 2021 | 1.97 Bn |
| Sep 30, 2021 | 1.29 Bn |
| Sep 30, 2021 | 1.29 Bn |
| Jun 30, 2021 | 1.39 Bn |
| Jun 30, 2021 | 1.39 Bn |
| Mar 31, 2021 | 1.40 Bn |
| Mar 31, 2021 | 1.40 Bn |
| Dec 31, 2020 | 1.36 Bn |
| Dec 31, 2020 | 1.36 Bn |
| Sep 30, 2020 | 1.41 Bn |
| Sep 30, 2020 | 1.41 Bn |
| Jun 30, 2020 | 2.21 Bn |
| Jun 30, 2020 | 2.21 Bn |
| Mar 31, 2020 | 124.10 Mn |
| Mar 31, 2020 | 124.10 Mn |
| Dec 31, 2019 | 1.64 Bn |
| Dec 31, 2019 | 1.64 Bn |
| Sep 30, 2019 | 1.25 Bn |
| Sep 30, 2019 | 1.25 Bn |
| Jun 30, 2019 | 811.20 Mn |
| Jun 30, 2019 | 811.20 Mn |
| Mar 31, 2019 | 107.60 Mn |
| Mar 31, 2019 | 107.60 Mn |
| Dec 31, 2018 | 1.05 Bn |
| Dec 31, 2018 | 1.05 Bn |
| Sep 30, 2018 | 1.85 Bn |
| Sep 30, 2018 | 1.85 Bn |
| Jun 30, 2018 | 1.21 Bn |
| Jun 30, 2018 | 1.21 Bn |
| Mar 31, 2018 | 200.00 Mn |
| Mar 31, 2018 | 200.00 Mn |
| Dec 31, 2017 | 1.30 Bn |
| Dec 31, 2017 | 1.30 Bn |
| Sep 30, 2017 | 1.64 Bn |
| Sep 30, 2017 | 1.64 Bn |
| Jun 30, 2017 | 1.43 Bn |
| Jun 30, 2017 | 1.43 Bn |
| Mar 31, 2017 | 170.90 Mn |
| Mar 31, 2017 | 170.90 Mn |
| Dec 31, 2016 | 1.60 Bn |
| Dec 31, 2016 | 1.60 Bn |
| Sep 30, 2016 | 1.43 Bn |
| Sep 30, 2016 | 1.43 Bn |
| Jun 30, 2016 | 1.16 Bn |
| Jun 30, 2016 | 1.16 Bn |
| Mar 31, 2016 | -373.40 Mn |
| Mar 31, 2016 | -373.40 Mn |
| Dec 31, 2015 | 615.90 Mn |
| Dec 31, 2015 | 615.90 Mn |
| Sep 30, 2015 | 831.20 Mn |
| Sep 30, 2015 | 831.20 Mn |
| Jun 30, 2015 | 724.70 Mn |
| Jun 30, 2015 | 724.70 Mn |
| Mar 31, 2015 | -273.40 Mn |
| Mar 31, 2015 | -273.40 Mn |
| Dec 31, 2014 | 1.03 Bn |
| Dec 31, 2014 | 1.03 Bn |
| Sep 30, 2014 | 1.39 Bn |
| Sep 30, 2014 | 1.39 Bn |
| Jun 30, 2014 | 799.00 Mn |
| Jun 30, 2014 | 799.00 Mn |
| Mar 31, 2014 | 70.30 Mn |
| Mar 31, 2014 | 70.30 Mn |
| Dec 31, 2013 | 1.26 Bn |
| Dec 31, 2013 | 1.26 Bn |
| Sep 30, 2013 | 1.74 Bn |
| Sep 30, 2013 | 1.74 Bn |
| Jun 30, 2013 | 1.50 Bn |
| Jun 30, 2013 | 1.50 Bn |
| Mar 31, 2013 | 221.50 Mn |
| Mar 31, 2013 | 221.50 Mn |
| Dec 31, 2012 | 1.19 Bn |
| Dec 31, 2012 | 1.19 Bn |
| Sep 30, 2012 | 1.36 Bn |
| Sep 30, 2012 | 1.36 Bn |
| Jun 30, 2012 | 1.13 Bn |
| Jun 30, 2012 | 1.13 Bn |
| Mar 31, 2012 | 721.80 Mn |
| Mar 31, 2012 | 721.80 Mn |
| Dec 31, 2011 | 1.69 Bn |
| Dec 31, 2011 | 1.69 Bn |
| Sep 30, 2011 | 1.90 Bn |
| Sep 30, 2011 | 1.90 Bn |
| Jun 30, 2011 | 1.90 Bn |
| Jun 30, 2011 | 1.90 Bn |
| Mar 31, 2011 | 1.07 Bn |
| Mar 31, 2011 | 1.07 Bn |
| Dec 31, 2010 | 1.98 Bn |
| Dec 31, 2010 | 1.98 Bn |
| Sep 30, 2010 | 1.60 Bn |
| Sep 30, 2010 | 1.60 Bn |
| Jun 30, 2010 | 1.76 Bn |
| Jun 30, 2010 | 1.76 Bn |
| Mar 31, 2010 | 832.90 Mn |
| Mar 31, 2010 | 832.90 Mn |
| Dec 31, 2009 | 1.76 Bn |
| Dec 31, 2009 | 1.76 Bn |
| Sep 30, 2009 | 1.13 Bn |
| Sep 30, 2009 | 1.13 Bn |
| Jun 30, 2009 | 746.40 Mn |
| Jun 30, 2009 | 746.40 Mn |
| Mar 31, 2009 | -69.10 Mn |
| Mar 31, 2009 | -69.10 Mn |